Researchers have discovered a serotonin type 3 receptor activator that produces an antidepressant effect in mice and functions independently of SSRIs.
A new method is up to 92% accurate in predicting which patients with bipolar disorder will respond to lithium.
A new study reports depressed people who responded to ketamine found their activity increased during earlier parts of the day. Researchers suggest clock gene machinery may be linked to the type of depression that responds to ketamine treatment.
Researchers report a monoclonal antibody that shows promise in the fight against cancer also appears to help reduce learning and memory problems associated with schizophrenia.
4E-BPs proteins are key to unlocking ketamine's antidepressant effects. When 4E-BPs are absent in neurons, ketamine can not produce its antidepressant effect.
Cannabidiol may buffer the effects of THC on the brain for those who use marijuana. Marijuana with a higher CBD content restores disruptions to the salience network caused by THC exposure.
As interest in using psychedelics to treat a range of mental health disorders grows, researchers consider the impact and therapeutic benefits of using psychedelics to help alleviate symptoms of depression.
Minocycline, a broad-spectrum tetracycline antibiotic, has shown promise in the treatment of depression. Researchers say the antibiotic could help reduce brain inflammation associated with some cases of major depressive disorder. A small study conducted by researchers at Deakin University found those treated with Minocycline reported improved quality of life, reduced anxiety symptoms and a better global impression of their depression.
A study using rat models of depression reveals a single dose of the cannabis extract CBD can help to reduce symptoms of depression for up to one week. Researchers say cannabidiol appears to activate mechanisms that help repair neural circuitry in the prefrontal cortex and hippocampus, which get damaged as a result of depression.
A new study reports LSD reduces connectivity in brain networks and interferes with patterns of activation which underlie thought and behavior.
A new study suggests that dysregulation in the way two G protein-coupled receptors talk to each other may be responsible for some symptoms of schizophrenia.
A growing body of evidence suggests psychedelics including psilocybin and LSD show promise in providing lasting relief from symptoms for those suffering some mental health disorders. Researchers found DOI, a similar drug to LSD, reduced negative behavioral responses following fear triggers in mouse models of anxiety.
